Cord Blood America Could Increase Sales With New Marketing Strategy: Analyst

Jun 10, 2010, 10:00 ET from Cord Blood America, Inc.

LAS VEGAS, June 10 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI) ( announced today that a new analyst report prepared by Francis Gaskins (, well known as one of the nation's leading IPO analysts, commented favorably in its Valuation Summary on Cord Blood America's planned new marketing strategy.

The new pricing policy, called "Afford-A-Cord," involves lowering the initial cost of storing a baby's stem cells from approximately $2000 to $495 plus the cost of shipping.  "With the new pricing policy, Cord Blood America may be able to significantly increase new account additions," Mr. Gaskins said.  The new program is set to launch on June 14, 2010.

Mr. Gaskin's report, which includes sections on CEO Updates and Interviews, News, a Growth Plan Summary, information on the Stem Cell Industry and what Cord Blood America provides its customers, plus information on its management team and directors, is available at:

"Cord Blood America is the only public company in the U.S. totally focused on the cord blood stem cell processing and storage market," Mr. Gaskins writes.  "With strong expected internal growth coupled with an aggressive, non-dilutive, roll-up acquisition strategy, we believe CBAI is a pure play in what is a fragmented industry."  These of course are purely Mr. Gaskins opinions, but management is optimistic that its new Afford-A-Cord will have a positive impact on sales.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at For investor information, visit


   Paul Knopick

   E & E Communications


IPOdesktop (ID) SAFE HARBOR STATEMENT: Statements contained in this document, including those pertaining to estimates and related plans, potential mergers and acquisitions, estimates, growth, establishing new markets, expansion into new markets and related plans other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. ID provides no assurance as to the subject company's plans or ability to effect any planned and/or proposed actions. ID has no first-hand knowledge of management and therefore cannot comment on its capabilities, intent, resources, nor experience and makes no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company or its agent and related sources believed by ID to be reliable, but ID provides no assurance, and none is given, as to the accuracy and completeness of this information.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

SOURCE Cord Blood America, Inc.